XÜLASƏ
İltihabi bağırsaq xəstəliyi (İBX) olan xəstələrə erkən diaqnoz, vaxtında və adekvat tibbi yardım problemi daxili xəstəliklər praktikasında aktual istiqamət olaraq qalır. Məqsəd. Azərbaycanda İBX olan xəstələrdə klinik gedişatının və konservativ müalicə üsullarını təhlil etmək. Materiallar və metodlar. Respublikanın müxtəlif regionlarından laboratoriya, endoskopik və patoloji müayinələrdən keçmiş 446 xəstənin (xoralı kolit (n=231), Kron xəstəliyi (n=190), mikroskopik kolit (n=20) və diferensiasiya edilməmiş kolit (n=5)) məlumat bazası təhlil edilmişdir. Nəticələr. Bu xəstə qrupunun demoqrafik və sosial-iqtisadi xüsusiyyətləri, o cümlədən xəstəliyin başlanğıcındakı orta yaş və diaqnozun qoyulma vaxtı (minimum və maksimum), əlillik vəziyyəti, klinik gedişat xüsusiyyətləri (fəsadlar və ekstraintestinal təzahürlər daxil olmaqla) və konservativ müalicə variantları təhlil edilmişdir. Yekun. İlkin xəstələr arasında ağır/mürəkkəb formaların yayılması, differensial diaqnostikada çətinliklər və tibbi yardımın mərhələlərində davamlılığın olmaması İBX xəstələrin vahid milli klinik reyestrinin yaradılmasını zəruri edir.
Açar sözlər: iltihabi bağırsaq xəstəlikləri, xoralı kolit, Kron xəstəliyi, kliniki gedişat

---

ƏDƏBİYYAT

1. Seyed Tabib NS, Madgwick M, Sudhakar P., et al. Big data in IBD: big progress for clinical practice // Gut. - 2020; 69:1520–32. doi:10.1136/gutjnl-2019-320065
2. Piovani D., Danese S., Peyrin-Biroulet L, et al. IBD: estimates from the global burden of disease 2017 study // Aliment Pharmacol Ther. - 2020; 51:261–70. doi:10.1111/apt. 15542
3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of İBD in the 21st century: a systematic review of population-based studies // Lancet. - 2017;390: 2769–78. doi:10.1016/S0140-6736(17)32448-0
4. Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019 // Lancet. - 2020; 396:1204–22. doi:10.1016/S0140-6736(20)30925-9
5. Qiu Y, Wen Ren W, Liu Y, et al. Disease burden of İBD in China from 1990 to 2017: Findings from the global burden of diseases 2017 // E Clinical Medicine. - 2020;27. 100544. http://www.journals.elsevier.com/eclinicalmedicine
6. Khalili H. The changing epidemiology of İBD: what goes up may come down // Inflamm Bowel Dis. - 2020; 26:591–2. doi:10.1093/ibd/izz186
7. Collaborators G. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019 // Lancet. - 2020; 396:1223–49. doi:10.1016/S0140-6736(20)30752-2
8. Ye Y, Manne S, Treem WR, et al. Prevalence of İBD in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016 // Inflamm Bowel Dis. - 2020; 26:619–25. doi:10.1093/ibd/izz182
9. Mak WY, Zhao M, Ng SC, et al. The epidemiology of İBD: East meets West // Journal of Gastroenterology and Hepatology - 2020; 35:380–389. doi:10.1111/jgh. 14872
10. Piovani D, Danese S, Peyrin-Biroulet L, et al. Environmental, nutritional, and socioeconomic determinants of IBD incidence: a global ecological study // J Crohns Colitis - 2020; 14:323–31. doi:10.1093/ecco-jcc/jjz150
11. Zhao M, Gönczi L, Lakatos PL, et al. The burden of İBD in Europe in 2020 // J Crohns Colitis. - 2021; 15:1573–87. doi:10.1093/ecco-jcc/jjab029
12. Shafer LA, Sofia MA, Rubin DT, et al. An international multicenter comparison of IBD-related disability and validation of the IBDDI // Clin Gastroenterol Hepatol. - 2021; 19:2524–31. doi: 10.1016/j.cgh.2020.08.053
13. Wang R, Li Z, Liu S, et al. Global, regional and national burden of İBD in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019 // BMJ Open. - 2023; 13:e065186. doi:10.1136/ bmjopen-2022-065186
14. Agrawal M, Jess T. Implications of the changing epidemiology of İBD in a changing world // United European Gastroenterol J. - 2022; 10:1113–20. doi:10. 1002/ ueg2.12317
15. Al Lawati TT, Al Rawahi Y, Al Bahlani AQ, Al Jamei A, Ramatalla D, Saadah OI. Incidence and clinical characteristics of pediatric İBD in Oman // Saudi J Gastroenterol. -2023; 29:177–82. doi: 10.4103/sjg.sjg_473_22
16. Князев О.В., Белоусова Е.А., Абдулганиева Д.И., и соавт. Реальная практика лекарственной терапии среднетяжелых и тяжелых форм ВЗК в России, Республике Беларусь, Республике Казахстан. Промежуточные результаты исследования INTENT //Альманах клинической медицины. - 2021;49(7):443–454.doi:10.18786/2072-0505-2021-49-061
17. Caron B., Honap S., Peyrin-Biroulet L. Epidemiology of IBD across the Ages in the Era of Advanced Therapies // J Crohns Colitis. - 2024; 18 (Suppl 2): ii3–ii15. doi: 10.1093/ecco-jcc/jjae082
18. Liu Y., Li J., Yang G., Meng D., Long X., Wang K. Global burden of in the elderly: trends from 1990 to 2021 and projections to 2051 // Front Aging. - 2024; 5:1479928. doi: 10.3389/fragi.2024.1479928
19. Akyuz F., Agargun B.F., Atug O., Eskazan T., Yuksel I., et al. Epidemiological Characteristics of Inflammatory Bowel Diseases in The Last Decade: Multi-Center Türkiye Data // Journal of Crohn's and Colitis. – 2024; Volume 18, Issue Supplement_1, i2025–i2027, https://doi.org/10.1093/ecco-jcc/jjad212.1261
20. Nielsen K.R., Midjord J., Lophaven S.N., Langholz E., Hammer T., Burisch J. The incidence and prevalence of İBD continues to increase in the Faroe Islands - a cohort study from 1960 to 2020 // J Crohns Colitis. -2024; 18, pp. 308-319
21. Rodríguez P.F., Agostini V.C., Natai S.-B., Almazán M.R., Torres E.A. Increase in Prevalence of IBD Among Insured Patients in Puerto Rico from 2018 to 2022 // The American Journal of Gastroenterology. - 2024. 119(12S): p S18, doi: 10.14309/01.ajg. 0001082796.75595.a9
22. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment // J Crohns Colitis. - 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180
23. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of İBD in adults // Gut. - 2019;68(Suppl 3): s1 —106. doi: 10.1136/gutjnl-2019-318484
24. Ciorba MA. Inflammatory bowel diseases 2024 // Curr Opin Gastroenterol. – 2024; 1;40(4):233-234. doi: 10.1097/MOG.0000000000001038. Epub 2024 Jun 6.
25. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis // Gastroenterology. - 2020;158(5):1450–61. doi: 10.1053/j.gastro.2020. 01.006
26. Zheng J, Fan Z, Li C, et al. Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis // BMJ Open Gastroenterol. - 2024;11:e001587. doi:10.1136/ bmjgast-2024-001587
27. Boyd T, Araka EB, Kochar B, et al. Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis // J Crohn's Colitis. - 2024; 18:570–7.
28. García MJ, Riestra S, Amiot A, et al. Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) // Aliment Pharmacol Ther. - 2024; 59:1248–59.
29. Alzahrani BA, Aljuhani JA, Badri ZA, Alshamrani RM, et al. The effect of smoking in İBD outcomes // Front. Gastroenterol. – 2024; 3:1395269. doi:10.3389/fgstr.2024.1395269
30. Johnson B. The impact of smoking duration on complications of ulcerative colitis: a prospective cohort study // Inflammatory Bowel Dis. – 2022; 45:213–20.
31. Johnson K, Singh R, Mehta P. Predictors of hospitalization and complications in İBD: A systematic review and meta-analysis // Inflammation Bowel Dis. -2021; 11 27:1398–409.
32. Gordon M, Darie AM, Sinopoulou V, et al. BSG 2024 IBD guidelines protocol (standard operating procedures) // BMJ Open Gastro. - 2023; 10: e001067. doi:10.1136/bmjgast-2022-001067
33. Gordon H., Minozzi S., Kopylov U., Verstockt B. et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment // Journal of Crohn's and Colitis. – 2024; Volume 18, Issue 10, Pages 1531–1555, https://doi.org/10.1093/ecco-jcc/jjae091
34. Raine T., Bonovas St., Burisch J., Kucharzik T., Adamina M. et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment // Journal of Crohn's and Colitis. -2022; Volume 16, Issue 1, Pages 2–17, https://doi.org/10.1093/ecco-jcc/jjab178
35. Safroneeva E, et al. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients // Aliment Pharmacol Ther. - 2015; 42:540–548.
36. Белоусова Е.А., Шелыгин Ю.А., Ачкасов С.И., и соавт. Клинико-демографические характеристики и лечебные подходы у пациентов с ВЗК в РФ. Первые результаты анализа Национального Регистра // Колопроктология. - 2023; т. 22, № 1, с. 65–82. https://doi.org/10.33878/2073-7556-2023-22-1-65-82
37. Gordon H., Burisch J., Ellul P., Karmiris K., Katsanos K., Allocca M. et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease // Journal of Crohn's and Colitis. – 2024;18;1;1–37, https://doi.org/10.1093/ecco-jcc/jjad108
38. Faggiani I., Fanizza J., D’Amico F., Allocca M., Zilli A. et al. Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment // Biomedicines. - 2024, 12(8), 1839; https://doi.org/10.3390/biomedicines12081839
39. Malik, T.F., & Aurelio, D.M. Extraintestinal manifestations of İBD // In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 33760556
40. Kilic Y., Kamal Sh., Jaffar F., Sriranganathan D., Quraishi M.N., Segal J.P. Prevalence of Extraintestinal Manifestations in IBD: A Systematic Review and Meta-analysis // Inflammatory Bowel Diseases 2024;30;2;230–239, https://doi.org/10.1093/ibd/izad061
41. Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult İBD in the United States: A systematic review // J Clin Pharm Ther. - 2019;44(4):495–507.
42. Algaba A, Guerra I, Ricart E, et al. Spanish GETECCU Group (ENEIDA Project). Extraintestinal manifestations in patients with İBD: study based on the ENEIDA Registry // Dig Dis Sci. - 2021;(66):2014-2023.